Bio-Techne Management
Management criteria checks 3/4
Bio-Techne's CEO is Chuck Kummeth, appointed in Apr 2013, has a tenure of 10.17 years. total yearly compensation is $15.37M, comprised of 7.7% salary and 92.3% bonuses, including company stock and options. directly owns 0.71% of the company’s shares, worth MX$1.51B. The average tenure of the management team and the board of directors is 2.4 years and 10.2 years respectively.
Key information
Chuck Kummeth
Chief executive officer
US$15.4m
Total compensation
| CEO salary percentage | 7.7% |
| CEO tenure | 10.2yrs |
| CEO ownership | 0.7% |
| Management average tenure | 2.4yrs |
| Board average tenure | 10.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | US$271m |
| Dec 31 2022 | n/a | n/a | US$262m |
| Sep 30 2022 | n/a | n/a | US$292m |
| Jun 30 2022 | US$15m | US$1m | US$272m |
| Mar 31 2022 | n/a | n/a | US$225m |
| Dec 31 2021 | n/a | n/a | US$210m |
| Sep 30 2021 | n/a | n/a | US$177m |
| Jun 30 2021 | US$16m | US$1m | US$140m |
| Mar 31 2021 | n/a | n/a | US$184m |
| Dec 31 2020 | n/a | n/a | US$175m |
| Sep 30 2020 | n/a | n/a | US$248m |
| Jun 30 2020 | US$11m | US$1m | US$229m |
| Mar 31 2020 | n/a | n/a | US$187m |
| Dec 31 2019 | n/a | n/a | US$195m |
| Sep 30 2019 | n/a | n/a | US$93m |
| Jun 30 2019 | US$11m | US$957k | US$96m |
| Mar 31 2019 | n/a | n/a | US$121m |
| Dec 31 2018 | n/a | n/a | US$96m |
| Sep 30 2018 | n/a | n/a | US$128m |
| Jun 30 2018 | US$10m | US$911k | US$126m |
| Mar 31 2018 | n/a | n/a | US$112m |
| Dec 31 2017 | n/a | n/a | US$114m |
| Sep 30 2017 | n/a | n/a | US$73m |
| Jun 30 2017 | US$9m | US$880k | US$76m |
| Mar 31 2017 | n/a | n/a | US$74m |
| Dec 31 2016 | n/a | n/a | US$82m |
| Sep 30 2016 | n/a | n/a | US$101m |
| Jun 30 2016 | US$7m | US$800k | US$104m |
Compensation vs Market: Chuck's total compensation ($USD15.37M) is above average for companies of similar size in the MX market ($USD5.70M).
Compensation vs Earnings: Chuck's compensation has been consistent with company performance over the past year.
CEO
Chuck Kummeth (63 yo)
10.2yrs
Tenure
US$15,370,548
Compensation
Mr. Charles R. Kummeth, also known as Chuck, has been the Chief Executive Officer and President of Bio-Techne Corporation since April 1, 2013 and served as its Chief Financial Officer since January 2014. M...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 10.2yrs | US$15.37m | 0.71% MX$ 1.5b | |
| Executive VP of Finance & CFO | 9.2yrs | US$4.44m | 0.032% MX$ 69.3m | |
| President of Diagnostics & Genomics | 5.2yrs | US$2.95m | 0.0097% MX$ 20.7m | |
| President of Protein Sciences Segment | 1.4yrs | US$2.80m | 0.0063% MX$ 13.5m | |
| Senior Director of Investor Relations & Corporate Development | no data | no data | no data | |
| Senior VP | less than a year | no data | 0.000090% MX$ 192.5k | |
| Vice President of Sales and Marketing | no data | no data | no data | |
| Vice President of Corporate Development | 2.4yrs | US$1.37m | no data | |
| Senior VP & Chief Human Resources Officer | 1.4yrs | no data | no data | |
| Managing Director | 6.9yrs | no data | no data | |
| Senior Vice President of Reagent Solutions Division | 2.4yrs | no data | no data | |
| Senior Vice President Of Molecular Diagnostics Division | 1.4yrs | no data | no data |
2.4yrs
Average Tenure
55.5yo
Average Age
Experienced Management: TECH *'s management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 10.2yrs | US$15.37m | 0.71% MX$ 1.5b | |
| Independent Chairman of the Board | 20.4yrs | US$410.14k | 0.027% MX$ 56.8m | |
| Independent Director | 14.1yrs | US$300.14k | 0.022% MX$ 47.5m | |
| Independent Director | 6.4yrs | US$275.14k | 0.0068% MX$ 14.5m | |
| Independent Director | 33.4yrs | US$292.64k | 0.014% MX$ 30.7m | |
| Independent Director | 13.1yrs | US$290.14k | 0.018% MX$ 39.1m | |
| Independent Director | 2.9yrs | US$275.14k | 0.0026% MX$ 5.5m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4yrs | US$275.14k | 0.0040% MX$ 8.5m | |
| Independent Director | 6.4yrs | US$275.14k | 0.0068% MX$ 14.5m | |
| Member of Scientific Advisory Board | no data | no data | no data |
10.2yrs
Average Tenure
63yo
Average Age
Experienced Board: TECH *'s board of directors are seasoned and experienced ( 10.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/13 14:29 |
| End of Day Share Price | 2023/03/16 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bio-Techne Corporation is covered by 27 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| James Francis Mainwaring | Atlantic Equities LLP |
| Catherine Ramsey Schulte | Baird |